The wave of breakthrough therapies in drug-based management of obesity has triggered a renaissance in metabolic disorders. As GLP-1 receptor agonists establish a new gold standard in weight-loss and first-in-class therapies demonstrate additional benefit in type 2 diabetes, stakeholders are flooding in to redefine the metabolic landscape.Uniting industry experts dedicated to accelerating the frontier of disease-modifying therapeutics beyond the current standard of care, the Novel Therapies for Type 2 Diabetes and Obesity Summit is the definitive industry forum sharing cross-industry insight to treat an exponentially growing patient population.From elucidating body weight set points to establish opportunities for therapeutic intervention, to demonstrating metabolic effect in diabetes to treat interrelated cardiorenal comorbidities, join industry experts including Novo Nordisk, Eli Lilly and Company, Altimmune, Regeneron, Boehringer Ingelheim, Amgen and more to navigate the pathway to regulatory approval for big pharma and smaller biotech.